TNT: Baseline and final LDL cholesterol levels

Slides:

Advertisements

Similar presentations

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Advertisements

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Managing the late consequences of CHD: What is the evidence for lipid management Prof Philip Barter The Heart Research Institute Sydney, Australia Slides.

On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs. 2004;9: LaRosa JC et al. N Engl J Med. 2005;352:

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Cholesterol quintile (mg/dL)

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Randomized, double-blind, multicenter, controlled trial.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Cholesterol Lowering and CV Risk: Meta-analyses. On-Treatment LDL and CHD Events in Statin Trials 2 Adapted from Rosenson RS. Expert Opin Emerg Drugs.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

The overwhelming case for LDL-C lowering

Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

TNT: Study Design Treating to New Targets

LEADER trial: Primary Outcome

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

AIM HIGH Niacin plus Statin to prevent vascular events

HDL cholesterol and cardiovascular risk Epidemiological evidence

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

HDL cholesterol and cardiovascular risk

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

TNT Study: Baseline Characteristics of the Patients

The Hypertension in the Very Elderly Trial (HYVET)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ASCOT-BPLA: Primary and secondary end points

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p for noninferiority < 0.001)

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Cystatin C levels and risk of death from all causes

Potential mechanisms whereby statins may reduce the risk of stroke

Daan Kromhout, et al. NEJM epub August 29, 2010

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Cause of death Treatment-arm events, % (n=45 054)

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

PROSPER: trial design

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

TNT diabetes analysis: Baseline and final LDL cholesterol levels

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

FIELD: Primary outcome

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

TNT: Baseline and final LDL cholesterol levels Atorvastatin 10 mg (n=5006) Atorvastatin 80 mg (n=4995) Mean baseline LDL cholesterol levels (mg/dL) 98 97 Final LDL cholesterol levels (mg/dL) 101 77 LaRosa JC et al. N Engl J Med 2005; available at: http://www.nejm.org.

TNT: Primary efficacy outcomes Atorvastatin 10 mg (n=5006) Atorvastatin 80 mg (n=4995) Hazard ratio (95% CI) p Total major cardiovascular events (%) 10.9 8.7 0.78 (0.69-0.89) <0.001 Death from coronary heart disease (%) 2.5 2.0 0.80 (0.61-1.03) 0.09 Nonfatal MI (%) 6.2 4.9 (0.66-0.93) 0.004 Resuscitation after cardiac arrest (%) 0.5 0.96 (0.56-1.67) 0.89 Fatal or nonfatal stroke (%) 3.1 2.3 0.75 (0.59-0.96) 0.02 LaRosa JC et al. N Engl J Med 2005; available at: http://www.nejm.org.